Robotic-Assisted versus Video-Assisted Thoracoscopic Lobectomy: Short-Term Results of a Randomized Clinical Trial (RVlob Trial).

Please login or register to bookmark this article
Bookmark this %label%

To determine whether robotic-assisted lobectomy (RAL) affects perioperative outcomes and long-term efficacy in non-small cell lung cancer (NSCLC) patients, compared with traditional video-assisted lobectomy (VAL).RAL is a promising treatment for NSCLC. However, its efficacy has not been fully evaluated.A single-center, open-labeled prospective randomized clinical trial was launched in May 2017 to compare the efficacy of RAL and VAL. By May 2020, 320 patients were enrolled. The perioperative results of RAL and VAL were compared.The 320 enrolled patients were randomly assigned to the RAL group (n = 157) and the VAL group (n = 163). Perioperative outcomes were comparable between the two groups, including the length of hospital stay (P = 0.76) and the rate of postoperative complications (P = 0.45). No perioperative mortality occurred in either group. The total amount of chest tube drainage (830 ml [IQR, 550-1130 ml] vs. 685 ml [IQR, 367.5-1160 ml], P = 0.007) and hospitalization costs ($12821 [IQR, $12145-$13924] vs. $8009 [IQR, $7014-$9003], P < 0.001) were significantly higher in the RAL group. RAL group had a significantly higher number of lymph nodes (LNs) harvested (11 [IQR, 8-15] vs. 10 [IQR, 8-13], P = 0.02), higher number of N1 LNs (6 [IQR, 4-8] vs. 5 [IQR, 3-7], P = 0.005), and more LN stations examined (6 [IQR, 5-7] vs. 5 [IQR, 4-6], P < 0.001).Both RAL and VAL are safe and feasible for the treatment of NSCLC. RAL achieved similar perioperative outcomes, together with higher LN yield. Further follow-up investigations are required to evaluate the long-term efficacy of RAL. ( identifier: NCT03134534).

View the full article @ Annals of surgery
Get PDF with LibKey

Authors: Runsen Jin, Yuyan Zheng, Ye Yuan, Dingpei Han, Yuqin Cao, Yajie Zhang, Chengqiang Li, Jie Xiang, Zhengyuan Zhang, Zhenyi Niu, Toni Lerut, Jules Lin, Abbas E Abbas, Alessandro Pardolesi, Takashi Suda, Dario Amore, Stefan Schraag, Clemens Aigner, Jian Li, Jiaming Che, Junbiao Hang, Jian Ren, Lianggang Zhu, Hecheng Li